About the Company
We do not have any company description for Silexion Therapeutics Corp at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Silexion Therapeutics Corp
Silexion Therapeutics Corp trading halted, news pending
(Bloomberg) -- Samsung Electronics Co. shares climbed after it said it has struck a 22.8 trillion won ($16.5 billion) agreement to produce chips for an unidentified client, a potentially big win for ...
Silexion Therapeutics Corp. Reports 2024 Financial Results and ... - Nasdaq
Silexion Therapeutics Corp. announced its financial results for the fourth quarter and full year ended December 31, 2024, highlighting a transformative year marked by its Nasdaq listing and ...
Silexion Therapeutics Corp. Reports Positive Preclinical Data for ...
Silexion Therapeutics Corp. announced promising preclinical data for its RNA interference therapy, SIL204, which has shown significant efficacy against human lung cancer cell lines with KRAS G12D ...
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% ...
Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference ...
Silexion Therapeutics Announces Positive Results in Preclinical Study ...
Grand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...
Silexion Therapeutics Announces New Preclinical Data ... - Morningstar
Company Contact Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com Capital Markets & IR Contact Arx Capital Markets North American Equities Desk silexion@arxadvisory.com ...
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering ...
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor ...
Silexion is actively exploring an expanded development plan for SIL204 using the systemic administration approach. Price Action: SLXN stock is up 25.23% at $1.39 at publication Wednesday. Read Next: ...
Silexion Therapeutics Unveils Innovative Expanded Development Plan for ...
Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering ...
Similar Companies
Loading the latest forecasts...